GLUCAGON RECEPTOR MODULATOR
or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions th...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Patent |
Sprache: | hrv ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | Didiuk, Mary Theresa Pfefferkorn, Jeffrey Allen Tu, Meihua Mike Guzman-Perez, Angel Filipski, Kevin James Lee, Esther Cheng Yin Stevens, Benjamin Dawson Aspnes, Gary Erik |
description | or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_HRP20161177TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HRP20161177TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_HRP20161177TT13</originalsourceid><addsrcrecordid>eNrjZJB29wl1dnT391MIcnV2DQjxD1Lw9XcJ9XEEsngYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSbxHUICRgaGZoaG5eUiIoTFxqgDxUCIl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>GLUCAGON RECEPTOR MODULATOR</title><source>esp@cenet</source><creator>Didiuk, Mary Theresa ; Pfefferkorn, Jeffrey Allen ; Tu, Meihua Mike ; Guzman-Perez, Angel ; Filipski, Kevin James ; Lee, Esther Cheng Yin ; Stevens, Benjamin Dawson ; Aspnes, Gary Erik</creator><creatorcontrib>Didiuk, Mary Theresa ; Pfefferkorn, Jeffrey Allen ; Tu, Meihua Mike ; Guzman-Perez, Angel ; Filipski, Kevin James ; Lee, Esther Cheng Yin ; Stevens, Benjamin Dawson ; Aspnes, Gary Erik</creatorcontrib><description>or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.</description><language>hrv ; eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20161104&DB=EPODOC&CC=HR&NR=P20161177T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20161104&DB=EPODOC&CC=HR&NR=P20161177T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Didiuk, Mary Theresa</creatorcontrib><creatorcontrib>Pfefferkorn, Jeffrey Allen</creatorcontrib><creatorcontrib>Tu, Meihua Mike</creatorcontrib><creatorcontrib>Guzman-Perez, Angel</creatorcontrib><creatorcontrib>Filipski, Kevin James</creatorcontrib><creatorcontrib>Lee, Esther Cheng Yin</creatorcontrib><creatorcontrib>Stevens, Benjamin Dawson</creatorcontrib><creatorcontrib>Aspnes, Gary Erik</creatorcontrib><title>GLUCAGON RECEPTOR MODULATOR</title><description>or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB29wl1dnT391MIcnV2DQjxD1Lw9XcJ9XEEsngYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSbxHUICRgaGZoaG5eUiIoTFxqgDxUCIl</recordid><startdate>20161104</startdate><enddate>20161104</enddate><creator>Didiuk, Mary Theresa</creator><creator>Pfefferkorn, Jeffrey Allen</creator><creator>Tu, Meihua Mike</creator><creator>Guzman-Perez, Angel</creator><creator>Filipski, Kevin James</creator><creator>Lee, Esther Cheng Yin</creator><creator>Stevens, Benjamin Dawson</creator><creator>Aspnes, Gary Erik</creator><scope>EVB</scope></search><sort><creationdate>20161104</creationdate><title>GLUCAGON RECEPTOR MODULATOR</title><author>Didiuk, Mary Theresa ; Pfefferkorn, Jeffrey Allen ; Tu, Meihua Mike ; Guzman-Perez, Angel ; Filipski, Kevin James ; Lee, Esther Cheng Yin ; Stevens, Benjamin Dawson ; Aspnes, Gary Erik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_HRP20161177TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>hrv ; eng</language><creationdate>2016</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>Didiuk, Mary Theresa</creatorcontrib><creatorcontrib>Pfefferkorn, Jeffrey Allen</creatorcontrib><creatorcontrib>Tu, Meihua Mike</creatorcontrib><creatorcontrib>Guzman-Perez, Angel</creatorcontrib><creatorcontrib>Filipski, Kevin James</creatorcontrib><creatorcontrib>Lee, Esther Cheng Yin</creatorcontrib><creatorcontrib>Stevens, Benjamin Dawson</creatorcontrib><creatorcontrib>Aspnes, Gary Erik</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Didiuk, Mary Theresa</au><au>Pfefferkorn, Jeffrey Allen</au><au>Tu, Meihua Mike</au><au>Guzman-Perez, Angel</au><au>Filipski, Kevin James</au><au>Lee, Esther Cheng Yin</au><au>Stevens, Benjamin Dawson</au><au>Aspnes, Gary Erik</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>GLUCAGON RECEPTOR MODULATOR</title><date>2016-11-04</date><risdate>2016</risdate><abstract>or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | hrv ; eng |
recordid | cdi_epo_espacenet_HRP20161177TT1 |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY |
title | GLUCAGON RECEPTOR MODULATOR |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T11%3A53%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Didiuk,%20Mary%20Theresa&rft.date=2016-11-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EHRP20161177TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |